Madhu Kumar
Stock Analyst at Goldman Sachs
(2.91)
# 1,608
Out of 4,944 analysts
150
Total ratings
56.44%
Success rate
20.45%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $113.33 | +49.12% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $6.54 | -8.26% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $24.71 | +5.22% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $12.86 | +32.19% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $2.00 | +100.00% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $143.62 | +7.92% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $34.31 | +54.47% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $4.98 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $17.80 | +310.11% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $23.90 | +489.96% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $12.97 | +162.14% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.23 | +169.06% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $14.89 | -5.98% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $10.58 | +98.49% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $13.39 | -62.66% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.29 | +249.34% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $6.80 | +1,209.79% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $5.61 | +2,039.04% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.44 | +2,172.73% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $10.86 | +682.69% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $2.66 | +1,366.17% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $14.30 | +298.60% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.40 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.70 | +52,841.18% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $4.36 | +359.24% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.02 | +9,703.92% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $32.20 | +8.70% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.32 | +18,452.88% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $10.75 | +272.09% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $23.91 | +2,007.90% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $429.93 | -46.50% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $13.07 | +8,507.50% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.83 | +4,701.92% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $27.12 | -20.72% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $56.60 | -58.48% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $113.33
Upside: +49.12%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $6.54
Upside: -8.26%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $24.71
Upside: +5.22%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $12.86
Upside: +32.19%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $2.00
Upside: +100.00%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $143.62
Upside: +7.92%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $34.31
Upside: +54.47%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.98
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $17.80
Upside: +310.11%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $23.90
Upside: +489.96%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $12.97
Upside: +162.14%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.23
Upside: +169.06%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $14.89
Upside: -5.98%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $10.58
Upside: +98.49%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $13.39
Upside: -62.66%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.29
Upside: +249.34%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $6.80
Upside: +1,209.79%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $5.61
Upside: +2,039.04%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.44
Upside: +2,172.73%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $10.86
Upside: +682.69%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $2.66
Upside: +1,366.17%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $14.30
Upside: +298.60%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.40
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.70
Upside: +52,841.18%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $4.36
Upside: +359.24%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.02
Upside: +9,703.92%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $32.20
Upside: +8.70%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.32
Upside: +18,452.88%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $10.75
Upside: +272.09%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $23.91
Upside: +2,007.90%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $429.93
Upside: -46.50%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $13.07
Upside: +8,507.50%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $0.83
Upside: +4,701.92%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $27.12
Upside: -20.72%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $56.60
Upside: -58.48%